Scott Rutchik, MD
Urology · Mishawaka, INNPI 1952356503
Payments from drug & device makers
Across 72 payments — averaging $42.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$2K
- Astellas Pharma US Inc$308
- Urogen Pharma, Inc.$156
- Terumo Medical Corporation$120
- Sumitomo Pharma America, Inc.$117
- Boston Scientific$111
- plus $533 from 20 others
What the payments were for
- Travel & lodging$1,60352%
- Food & beverage$1,35644%
- Education$1264%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 11 | $1,741 |
| Astellas Pharma US Inc | 14 | $308 |
| Urogen Pharma, Inc. | 6 | $156 |
| Terumo Medical Corporation | 1 | $120 |
| Sumitomo Pharma America, Inc. | 7 | $117 |
| Boston Scientific | 3 | $111 |
| Progenics Pharmaceuticals, Inc. | 4 | $78 |
| AbbVie(2 entities) | 4 | $65 |
| 180 Medical, Inc. | 2 | $53 |
| Johnson & Johnson | 2 | $36 |
| Bayer | 2 | $32 |
| Argenx US, Inc. | 1 | $30 |
| Healthtronics Stone Solutions, LLC | 2 | $26 |
| Novartis | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Olympus America Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Profound Medical Corp. | 1 | $19 |
| Merck | 1 | $14 |
| Urovant Sciences Inc | 1 | $14 |
| Blue Earth Diagnostics | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,086 in reported general payments places this provider in the 45th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 178 | $169,402 |
| GemtesaVibegron | 78 | $82,682 |
| Tamsulosin Hcl | 492 | $7,568 |
| Solifenacin Succinate | 73 | $3,163 |
| Finasteride | 281 | $3,087 |
| Methenamine Hippurate | 66 | $2,918 |
| Trospium Chloride | 64 | $2,658 |
| Potassium Citrate ErPotassium Citrate | 15 | $2,188 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 89 | $1,831 |
| Dutasteride | 29 | $1,780 |
| Trospium Chloride ErTrospium Chloride | 13 | $1,754 |
| Tolterodine Tartrate ErTolterodine Tartrate | 32 | $715 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 61 | $676 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $538 |
| Oxybutynin Chloride | 42 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $308 | $169,402178 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $117 | $82,68278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 272 urology providers in Indiana.
Other urology in Mishawaka
- Ryan MaloneJeffersonville$7.1M
- James BailenJeffersonville$5.9M
- Eugene ConeGreenwood$2.1M
- Chad ReichardCarmel$1.3M
- Alexander TatemCarmel$441K
- Marcelino RiveraIndianapolis$382K
- Manoj RaoMerrillville$367K
- Hristos KaimakliotisIndianapolis$316K
- Jason KovacCarmel$248K
- Michael BorofskyIndianapolis$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.